Study of Once-Daily 5% Minoxidil Foam for Treating Female Pattern Hair Loss in Adults

What this Trial Is About

Researchers are evaluating the effectiveness of a once-daily 5% minoxidil foam compared to a placebo in women with androgenetic alopecia. This study aims to measure hair growth improvements using the Target Area Terminal Hair Count TAHC as the main endpoint. It is a Phase 3, randomized, double-blind, placebo-controlled trial sponsored by Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. Participants will apply either 5% minoxidil foam or a placebo foam once daily, in the morning or evening, with a maximum dose of 1 gram per day for up to 24 weeks. The study involves two groups one receiving the active foam and the other receiving placebo. Treatment adherence and effects will be monitored throughout the 24-week period. During the study, participants will undergo digital phototrichogram analysis at weeks 6, 12, 18, and 24 to measure changes in hair count. They will also self-assess their satisfaction at these times. Safety and efficacy will be evaluated through these measures, with the main outcome assessed at week 24. The total participation duration is approximately 24 weeks.

Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia